ProMIS Neurosciences Inc PMN

Incoming . Hopefully not 8 cents again

[Thenorth1990]

Aprominent panel of medical experts unanimously voted that there is no evidence to suggest the recently approved Alzheimers drug offers patients any health benefits beyond the usual care. The meeting, which was convened to review both clinical and cost effectiveness of the new drug, is the latest blow to Biogen (BIIB) and its efforts to win acceptance amid a firestorm of controversy over study data and its dealings with the Food and Drug Administration. PHARMALOT Pharmalittle: ICER medical experts find no benefit for Aduhelm; FDA panel votes down Fibrogens anemia drug By ELIZABETH PHARMALOT Pharmalittle: FDA head admits possible missteps in Alzheimers drug approval; two major health systems wont administer Biogen drug By ED SILVERMAN

[M101]

LMAO, how about this version at Politico:  "INFLUENTIAL DRUG PRICING PANEL SEES NO BENEFIT FROM ADUHELM — An expert panel convened by the Institute for Clinical and Economic Review concluded Thursday that the controversial Alzheimer's drug does not work better than existing forms of care — and isn’t worth Biogen’s $56,000 price tag. The group rendered its verdict as a